Guanylyl cyclase C as a biomarker in colorectal cancer

Biomarkers in Medicine

Volumn 7, Issue 1, 2013, Pages 159-167

  Hyslop, Terry ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

biomarker; colorectal cancer; guanylyl cyclase C; molecular staging; occult tumor burden; prediction; prognosis; quantitative reverse transcription PCR; regional lymph node network; RT qPCR; staging

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; GUANYLATE CYCLASE; GUANYLYL CYCLASE C; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG;

CANCER INHIBITION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL SURGERY; HUMAN; LYMPH NODE METASTASIS; NONHUMAN; RACE DIFFERENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; TREATMENT RESPONSE; TUMOR VOLUME;

COLORECTAL NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84873466594     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.90     Document Type: Review

References (56)

1. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J. Clin. 54(6), 295-308 (2004).
2. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 375(9719), 1030-1047 (2010).
3. American Joint Committee on Cancer. AJCC Cancer Staging Manual (7th Edition). Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). Springer, NY, USA (2009).
4. Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann. Surg. Oncol. 13(11), 1386-1392 (2006).
5. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J. Mol. Diagn. 9(5), 563-571 (2007).
6. Chien C, Morimoto LM, Tom J, Li Ci. Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer 104(3), 629-639 (2005).
7. Le H, Ziogas A, Lipkin SM, Zell JA. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol. Biomarkers Prev. 17(8), 1950-1962 (2008).
8. Marcella S, Miller JE. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J. Clin. Epidemiol. 54(4), 359-366 (2001).
9. Soneji S, Iyer SS, Armstrong K, Asch DA. Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am. J. Public Health 100(10), 1912-1916 (2010).
10. Grothey A. Does stage II colorectal cancer need to be redefined? Clin. Cancer Res. 17(10), 3053-3055 (2011).
11. Waldman SA, Hyslop T, Schulz S et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 301(7), 745-752 (2009).
12. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer 118(9), 2532-2540 (2012).
13. Hyslop T, Weinberg Ds, Schulz S, Barkun A, Waldman SA. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin. Cancer Res. 17(10), 3293-3303 (2011).
14. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. J. Surg. Oncol. 106(1), 24-30 (2012).
15. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212-236 (2011).
16. Ratto C, Sofo L, Ippoliti M et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis. Colon Rectum 42(2), 143-154 (1999).
17. Radel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol. 23(34), 8688-8696 (2005).
18. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005).
19. Benson AB, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408-3419 (2004).
20. Iddings D, Bilchik A. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J. Surg. Oncol. 96(8), 671-677 (2007).
21. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med. Clin. North Am. 89(4), 771-793 (2005).
22. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J. Clin. Oncol. 24(14), 2179-2187 (2006).
23. Laiyemo AO, Doubeni C, Pinsky PF et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J. Natl Cancer Inst. 102(8), 538-546 (2010).
24. Mayberry RM, Coates RJ, Hill HA et al. Determinants of black/white differences in colon cancer survival. J. Natl Cancer Inst. 87(22), 1686-1693 (1995).
25. White A, Vernon SW, Franzini L, Du XL. Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics? Cancer 116(19), 4622-4631 (2010).
26. Chen Vw, Fenoglio-Preiser CM, Wu XC et al. Aggressiveness of colon carcinoma in blacks and whites. National cancer institute black/white cancer survival study group. Cancer Epidemiol. Biomarkers Prev. 6(12), 1087-1093 (1997).
27. Bilchik AJ, Hoon DS, Saha S et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann. Surg. 246(4), 568-575 (2007).
28. Cagir B, Gelmann A, Park J et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann. Intern. Med. 131(11), 805-812 (1999).
29. Liefers GJ, Cleton-Jansen AM, van de Velde CJ et al. Micrometastases and survival in stage II colorectal cancer. N. Engl. J. Med. 339(4), 223-228 (1998).
30. Carrithers SL, Barber MT, Biswas S et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc. Natl Acad. Sci. USA 93(25), 14827-14832 (1996).
31. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev. Mol. Diagn. 5(5), 701-713 (2005).
32. Pitari GM, Li P, Lin JE et al. The paracrine hormone hypothesis of colorectal cancer. Clin. Pharmacol. Ther. 82(4), 441-447 (2007).
33. Birkenkamp-Demtroder K, Lotte Christensen L, Harder Olesen S et al. Gene expression in colorectal cancer. Cancer Res. 62, 4352-4363 (2002).
34. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61(7), 3124-3130 (2001).
35. Shailubhai K, Yu HH, Karunanandaa K et al. Uroguanylin treatment suppresses polyp formation in the ApcMin/+ mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 60(18), 5151-5157 (2000).
36. Steinbrecher KA, Tuohy TM, Heppner Goss K et al. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem. Biophys. Res. Commun. 273(1), 225-230 (2000).
37. Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol. 171(6), 1847-1858 (2007).
38. Li P, Schulz S, Bombonati A et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133(2), 599-607 (2007).
39. Lin JE, Li P, Snook AE et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 138(1), 241-254 (2010).
40. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol. 36(2), 170-179 (2005).
41. Schulz S, Hyslop T, Haaf J et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res. 12(15), 4545-4552 (2006).
42. Witek ME, Nielsen K, Walters R et al. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin. Cancer Res. 11(24 Pt 1), 8549-8556 (2005).
43. Waldman SA, Cagir B, Rakinic J et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis. Colon Rectum 41(3), 310-315 (1998).
44. Chervoneva I, Hyslop T, Iglewicz B et al. Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 348(2), 198-208 (2006).
45. Chervoneva I, Li Y, Iglewicz B, Waldman S, Hyslop T. Relative quantification based on logistic models for individual polymerase chain reactions. Stat. Med. 26(30), 5596-5611 (2007).
46. Beaulieu M, Desaulniers M, Bertrand N et al. Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer. Diagn. Mol. Pathol. 19(1), 20-27 (2010).
47. Haince JF, Houde M, Beaudry G et al. Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. J. Clin. Pathol. 63(6), 530-537 (2010).
48. Sargent DJ, Resnick MB, Meyers MO et al. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. Ann. Surg. Oncol. 18(12), 3261-3270 (2011).
49. Croner RS, Peters A, Brueckl WM et al. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 104(2), 395-404 (2005).
50. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat. Genet. 38(5), 540-549 (2006).
51. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J Med. 331(4), 213-221 (1994).
52. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
53. Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22(9), 1564-1571 (2004).
54. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
55. Wilson C, Schulz S, Waldman S. Cancer biomarkers: where medicine, business, and public policy intersect. Biotechnol. Healthc. February, 1-7 (2007).
56. Wilson C, Schulz S, Waldman SA. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Clin. Pharmacol. Ther. 81(2), 153-155 (2007).